Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

A Pilot Randomized Sham-Controlled Trial of MC5-A Scrambler Therapy in the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN).

Smith TJ, Razzak AR, Blackford AL, Ensminger J, Saiki C, Longo-Schoberlein D, Loprinzi CL.

J Palliat Care. 2019 Feb 3:825859719827589. doi: 10.1177/0825859719827589. [Epub ahead of print]

PMID:
30714486
2.

Clinical Differences in COPD Patients with Variable Patterns of Hypoxemia.

Narewski ER, Blackford AL, Lammi MR, Fuhlbrigge AL, Soler X, Albert R, Criner GJ; Long-Term Oxygen Treatment Trial Research Group.

Chronic Obstr Pulm Dis. 2018 Apr 28;5(3):167-176. doi: 10.15326/jcopdf.5.3.2017.0175.

3.

In proportion: approaches for displaying patient-reported outcome research study results as percentages responding to treatment.

Tolbert E, Brundage M, Bantug E, Blackford AL, Smith K, Snyder C; PRO Data Presentation Stakeholder Advisory Board.

Qual Life Res. 2018 Nov 29. doi: 10.1007/s11136-018-2065-3. [Epub ahead of print]

PMID:
30498892
4.

Prevalence of comorbidities and effect on survival in survivors of human papillomavirus-related and human papillomavirus-unrelated head and neck cancer in the United States.

Eytan DF, Blackford AL, Eisele DW, Fakhry C.

Cancer. 2019 Jan 15;125(2):249-260. doi: 10.1002/cncr.31800. Epub 2018 Nov 16.

PMID:
30444527
5.

Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy.

Knaus HA, Berglund S, Hackl H, Blackford AL, Zeidner JF, Montiel-Esparza R, Mukhopadhyay R, Vanura K, Blazar BR, Karp JE, Luznik L, Gojo I.

JCI Insight. 2018 Nov 2;3(21). pii: 120974. doi: 10.1172/jci.insight.120974. [Epub ahead of print]

6.

Topical Estrogen Prescription Fill Rates for Women With a History of Breast Cancer Who Are Taking Hormone Therapy.

Huntley JH, Richter LA, Blackford AL, Aliu O, Pollack CE.

Obstet Gynecol. 2018 Nov;132(5):1137-1142. doi: 10.1097/AOG.0000000000002914.

PMID:
30303924
7.

Prevalence of Comorbidities among Older Head and Neck Cancer Survivors in the United States.

Eytan DF, Blackford AL, Eisele DW, Fakhry C.

Otolaryngol Head Neck Surg. 2019 Jan;160(1):85-92. doi: 10.1177/0194599818796163. Epub 2018 Sep 25.

PMID:
30252608
8.

Picture This: Presenting Longitudinal Patient-Reported Outcome Research Study Results to Patients.

Tolbert E, Brundage M, Bantug E, Blackford AL, Smith K, Snyder C; PRO Data Presentation Stakeholder Advisory Board.

Med Decis Making. 2018 Nov;38(8):994-1005. doi: 10.1177/0272989X18791177. Epub 2018 Aug 22.

PMID:
30132393
9.

Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML).

Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE.

Leuk Res. 2018 Sep;72:92-95. doi: 10.1016/j.leukres.2018.08.005. Epub 2018 Aug 10. No abstract available.

PMID:
30118897
10.

A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.

Santa-Maria CA, Bardia A, Blackford AL, Snyder C, Connolly RM, Fetting JH, Hayes DF, Jeter SC, Miller RS, Nguyen A, Quinlan K, Rosner GL, Slater S, Storniolo AM, Wolff AC, Zorzi J, Henry NL, Stearns V.

Breast Cancer Res Treat. 2018 May 11. doi: 10.1007/s10549-018-4811-1. [Epub ahead of print]

PMID:
29752687
11.

A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure.

Zeidan AM, Knaus HA, Robinson TM, Towlerton AMH, Warren EH, Zeidner JF, Blackford AL, Duffield AS, Rizzieri D, Frattini MG, Levy YM, Schroeder MA, Ferguson A, Sheldon KE, DeZern AE, Gojo I, Gore SD, Streicher H, Luznik L, Smith BD.

Clin Cancer Res. 2018 Aug 1;24(15):3519-3527. doi: 10.1158/1078-0432.CCR-17-3763. Epub 2018 May 1.

PMID:
29716921
12.

Pilot randomized controlled trial of a comprehensive smoking cessation intervention for patients with upper aerodigestive cancer undergoing radiotherapy.

Rettig EM, Fakhry C, Hales RK, Kisuule F, Quon H, Kiess AP, Yin LX, Zhang Y, Blackford AL, Drummond MB, Gourin CG, Koch WM, Eisele DW, D'Souza G.

Head Neck. 2018 Jul;40(7):1534-1547. doi: 10.1002/hed.25148. Epub 2018 Mar 15.

PMID:
29542262
13.

Underutilization of Treatment for Regional Gastric Cancer Among the Elderly in the USA.

Liu N, Molena D, Stem M, Blackford AL, Sewell DB, Lidor AO.

J Gastrointest Surg. 2018 Jun;22(6):955-963. doi: 10.1007/s11605-018-3691-3. Epub 2018 Feb 5.

PMID:
29404983
14.

Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.

Webster JA, Tibes R, Morris L, Blackford AL, Litzow M, Patnaik M, Rosner GL, Gojo I, Kinders R, Wang L, Doyle LA, Huntoon CJ, Karnitz LM, Kaufmann SH, Karp JE, Smith BD.

Leuk Res. 2017 Oct;61:108-116. doi: 10.1016/j.leukres.2017.09.005. Epub 2017 Sep 20.

15.

Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation.

Imus PH, Blackford AL, Bettinotti M, Iglehart B, Dietrich A, Tucker N, Symons H, Cooke KR, Luznik L, Fuchs EJ, Brodsky RA, Matsui WH, Huff CA, Gladstone D, Ambinder RF, Borrello IM, Swinnen LJ, Jones RJ, Bolaños-Meade J.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1887-1894. doi: 10.1016/j.bbmt.2017.07.014. Epub 2017 Jul 25.

16.

A Software Application for Mining and Presenting Relevant Cancer Clinical Trials per Cancer Mutation.

Gandy LM, Gumm J, Blackford AL, Fertig EJ, Diaz LA Jr.

Cancer Inform. 2017 Jun 22;16:1176935117711940. doi: 10.1177/1176935117711940. eCollection 2017.

17.

Erratum to: Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications.

Cintolo-Gonzalez JA, Braun D, Blackford AL, Mazzola E, Acar A, Plichta JK, Griffin M, Hughes KS.

Breast Cancer Res Treat. 2017 Aug;164(3):745. doi: 10.1007/s10549-017-4349-7. No abstract available.

PMID:
28639028
18.

A Single Center Survey of Health-Related Quality of Life among Acute Myeloid Leukemia Survivors in First Complete Remission.

Cheng MJ, Smith BD, Hourigan CS, Gojo I, Pratz KW, Blackford AL, Mehta AK, Smith TJ.

J Palliat Med. 2017 Nov;20(11):1267-1273. doi: 10.1089/jpm.2017.0069. Epub 2017 May 24.

19.

Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications.

Cintolo-Gonzalez JA, Braun D, Blackford AL, Mazzola E, Acar A, Plichta JK, Griffin M, Hughes KS.

Breast Cancer Res Treat. 2017 Jul;164(2):263-284. doi: 10.1007/s10549-017-4247-z. Epub 2017 Apr 25. Review. Erratum in: Breast Cancer Res Treat. 2017 Aug;164(3):745.

PMID:
28444533
20.

Duodenal Involvement is an Independent Prognostic Factor for Patients with Surgically Resected Pancreatic Ductal Adenocarcinoma.

Dal Molin M, Blackford AL, Siddiqui A, Brant A, Cho C, Rezaee N, Yu J, He J, Weiss M, Hruban RH, Wolfgang C, Goggins M.

Ann Surg Oncol. 2017 Aug;24(8):2379-2386. doi: 10.1245/s10434-017-5864-9. Epub 2017 Apr 24.

PMID:
28439733
21.

Estimating TP53 Mutation Carrier Probability in Families with Li-Fraumeni Syndrome Using LFSPRO.

Peng G, Bojadzieva J, Ballinger ML, Li J, Blackford AL, Mai PL, Savage SA, Thomas DM, Strong LC, Wang W.

Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):837-844. doi: 10.1158/1055-9965.EPI-16-0695. Epub 2017 Jan 30.

22.

What do these scores mean? Presenting patient-reported outcomes data to patients and clinicians to improve interpretability.

Snyder CF, Smith KC, Bantug ET, Tolbert EE, Blackford AL, Brundage MD; PRO Data Presentation Stakeholder Advisory Board.

Cancer. 2017 May 15;123(10):1848-1859. doi: 10.1002/cncr.30530. Epub 2017 Jan 13.

23.

Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma.

Poruk KE, Blackford AL, Weiss MJ, Cameron JL, He J, Goggins M, Rasheed ZA, Wolfgang CL, Wood LD.

Clin Cancer Res. 2017 Jun 1;23(11):2681-2690. doi: 10.1158/1078-0432.CCR-16-1467. Epub 2016 Oct 27.

24.

A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation.

Long-Term Oxygen Treatment Trial Research Group, Albert RK, Au DH, Blackford AL, Casaburi R, Cooper JA Jr, Criner GJ, Diaz P, Fuhlbrigge AL, Gay SE, Kanner RE, MacIntyre N, Martinez FJ, Panos RJ, Piantadosi S, Sciurba F, Shade D, Stibolt T, Stoller JK, Wise R, Yusen RD, Tonascia J, Sternberg AL, Bailey W.

N Engl J Med. 2016 Oct 27;375(17):1617-1627.

25.

Obstructive Sleep Apnea and Pathological Characteristics of Resected Pancreatic Ductal Adenocarcinoma.

Dal Molin M, Brant A, Blackford AL, Griffin JF, Shindo K, Barkley T, Rezaee N, Hruban RH, Wolfgang CL, Goggins M.

PLoS One. 2016 Oct 12;11(10):e0164195. doi: 10.1371/journal.pone.0164195. eCollection 2016.

26.

Adjuvant radiation use in older women with early-stage breast cancer at Johns Hopkins.

Pollock YG, Blackford AL, Jeter SC, Wright J, Cimino-Mathews A, Camp M, Harvey S, Asrari F, Schoenborn NL, Stearns V.

Breast Cancer Res Treat. 2016 Nov;160(2):291-296. Epub 2016 Oct 3.

27.

Esophageal Cancer Treatment Is Underutilized Among Elderly Patients in the USA.

Molena D, Stem M, Blackford AL, Lidor AO.

J Gastrointest Surg. 2017 Jan;21(1):126-136. doi: 10.1007/s11605-016-3229-5. Epub 2016 Aug 15.

28.

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.

Gojo I, Beumer JH, Pratz KW, McDevitt MA, Baer MR, Blackford AL, Smith BD, Gore SD, Carraway HE, Showel MM, Levis MJ, Dezern AE, Gladstone DE, Ji JJ, Wang L, Kinders RJ, Pouquet M, Ali-Walbi I, Rudek MA, Poh W, Herman JG, Karnitz LM, Kaufmann SH, Chen A, Karp JE.

Clin Cancer Res. 2017 Feb 1;23(3):697-706. doi: 10.1158/1078-0432.CCR-16-0984. Epub 2016 Aug 8.

29.

Relationship Between Quality of Comorbid Condition Care and Costs for Cancer Survivors.

Frick KD, Snyder CF, Herbert RJ, Blackford AL, Neville BA, Wolff AC, Carducci MA, Earle CC.

J Oncol Pract. 2016 Jun;12(6):e734-45. doi: 10.1200/JOP.2015.006098. Epub 2016 May 10.

30.

Comparing Prognostic Tools for Cancer Screening: Considerations for Clinical Practice and Performance Assessment.

Pollack CE, Blackford AL, Schoenborn NL, Boyd CM, Peairs KS, DuGoff EH.

J Am Geriatr Soc. 2016 May;64(5):1032-8. doi: 10.1111/jgs.14089. Epub 2016 Apr 30.

31.

PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.

Rowe SP, Macura KJ, Mena E, Blackford AL, Nadal R, Antonarakis ES, Eisenberger M, Carducci M, Fan H, Dannals RF, Chen Y, Mease RC, Szabo Z, Pomper MG, Cho SY.

Mol Imaging Biol. 2016 Jun;18(3):411-9. doi: 10.1007/s11307-016-0957-6.

32.

Rising population of survivors of oral squamous cell cancer in the United States.

Patel MA, Blackford AL, Rettig EM, Richmon JD, Eisele DW, Fakhry C.

Cancer. 2016 May 1;122(9):1380-7. doi: 10.1002/cncr.29921. Epub 2016 Mar 7.

33.

Association of acute myeloid leukemia's most immature phenotype with risk groups and outcomes.

Gerber JM, Zeidner JF, Morse S, Blackford AL, Perkins B, Yanagisawa B, Zhang H, Morsberger L, Karp J, Ning Y, Gocke CD, Rosner GL, Smith BD, Jones RJ.

Haematologica. 2016 May;101(5):607-16. doi: 10.3324/haematol.2015.135194. Epub 2016 Jan 27.

34.

A two-stage approach to genetic risk assessment in primary care.

Biswas S, Atienza P, Chipman J, Blackford AL, Arun B, Hughes K, Parmigiani G.

Breast Cancer Res Treat. 2016 Jan;155(2):375-83. doi: 10.1007/s10549-016-3686-2. Epub 2016 Jan 19.

35.

Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma.

Poruk KE, Valero V 3rd, Saunders T, Blackford AL, Griffin JF, Poling J, Hruban RH, Anders RA, Herman J, Zheng L, Rasheed ZA, Laheru DA, Ahuja N, Weiss MJ, Cameron JL, Goggins M, Iacobuzio-Donahue CA, Wood LD, Wolfgang CL.

Ann Surg. 2016 Dec;264(6):1073-1081.

36.

Improving an electronic system for measuring PROs in routine oncology practice.

Wu AW, White SM, Blackford AL, Wolff AC, Carducci MA, Herman JM, Snyder CF; PatientViewpoint Scientific Advisory Board.

J Cancer Surviv. 2016 Jun;10(3):573-82. doi: 10.1007/s11764-015-0503-6. Epub 2015 Dec 7.

37.

Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute.

Zeidner JF, Karp JE, Blackford AL, Foster MC, Dees EC, Smith G, Ivy SP, Harris P.

J Natl Cancer Inst. 2015 Nov 9;108(3). doi: 10.1093/jnci/djv335. Print 2016 Mar.

38.

Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.

Kanakry JA, Gocke CD, Bolaños-Meade J, Gladstone DE, Swinnen LJ, Blackford AL, Fuchs EJ, Huff CA, Borrello I, Matsui WH, Brodsky RA, Rosner GL, Shanbhag S, Luznik L, Jones RJ, Ambinder RF, Kasamon YL.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2115-2122. doi: 10.1016/j.bbmt.2015.07.012. Epub 2015 Jul 14.

39.

Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.

Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE.

Haematologica. 2015 Sep;100(9):1172-9. doi: 10.3324/haematol.2015.125849. Epub 2015 May 28.

40.

Comorbid condition care quality in cancer survivors: role of primary care and specialty providers and care coordination.

Snyder CF, Frick KD, Herbert RJ, Blackford AL, Neville BA, Lemke KW, Carducci MA, Wolff AC, Earle CC.

J Cancer Surviv. 2015 Dec;9(4):641-9. doi: 10.1007/s11764-015-0440-4. Epub 2015 Feb 26.

41.

Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages.

Yu J, Blackford AL, Dal Molin M, Wolfgang CL, Goggins M.

Gut. 2015 Nov;64(11):1783-9. doi: 10.1136/gutjnl-2014-308653. Epub 2015 Jan 30.

42.

Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience.

Wolff AC, Blackford AL, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, Stockerl-Goldstein K, Neumayer L, Langbaum TS, Theriault RL, Hughes ME, Weeks JC, Karp JE.

J Clin Oncol. 2015 Feb 1;33(4):340-8. doi: 10.1200/JCO.2013.54.6119. Epub 2014 Dec 22. Erratum in: J Clin Oncol. 2015 Apr 1;33(10):1227.

43.

Identifying changes in scores on the EORTC-QLQ-C30 representing a change in patients' supportive care needs.

Snyder CF, Blackford AL, Sussman J, Bainbridge D, Howell D, Seow HY, Carducci MA, Wu AW.

Qual Life Res. 2015 May;24(5):1207-16. doi: 10.1007/s11136-014-0853-y. Epub 2014 Nov 15.

44.

When using patient-reported outcomes in clinical practice, the measure matters: a randomized controlled trial.

Snyder CF, Herman JM, White SM, Luber BS, Blackford AL, Carducci MA, Wu AW.

J Oncol Pract. 2014 Sep;10(5):e299-306. doi: 10.1200/JOP.2014.001413. Epub 2014 Jul 1.

45.

Intrapancreatic accessory spleen: possibilities of computed tomography in differentiation from nonfunctioning pancreatic neuroendocrine tumor.

Coquia SF, Kawamoto S, Zaheer A, Bleich KB, Blackford AL, Hruban RH, Fishman EK.

J Comput Assist Tomogr. 2014 Nov-Dec;38(6):874-8. doi: 10.1097/RCT.0000000000000127.

46.

It's who you know: patient-sharing, quality, and costs of cancer survivorship care.

Pollack CE, Frick KD, Herbert RJ, Blackford AL, Neville BA, Wolff AC, Carducci MA, Earle CC, Snyder CF.

J Cancer Surviv. 2014 Jun;8(2):156-66. doi: 10.1007/s11764-014-0349-3. Epub 2014 Feb 28.

47.

Treatment, survival, and costs of laryngeal cancer care in the elderly.

Gourin CG, Dy SM, Herbert RJ, Blackford AL, Quon H, Forastiere AA, Eisele DW, Frick KD.

Laryngoscope. 2014 Aug;124(8):1827-35. doi: 10.1002/lary.24574. Epub 2014 Feb 11.

PMID:
24515616
48.

Quality indicators of laryngeal cancer care in the elderly.

Gourin CG, Frick KD, Blackford AL, Herbert RJ, Quon H, Forastiere AA, Eisele DW, Dy SM.

Laryngoscope. 2014 Sep;124(9):2049-56. doi: 10.1002/lary.24593. Epub 2014 Feb 22.

PMID:
24431293
49.

A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.

Zeidner JF, Karp JE, Blackford AL, Smith BD, Gojo I, Gore SD, Levis MJ, Carraway HE, Greer JM, Ivy SP, Pratz KW, McDevitt MA.

Haematologica. 2014 Apr;99(4):672-8. doi: 10.3324/haematol.2013.097246. Epub 2013 Dec 20.

50.

Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma.

Herman JM, Fan KY, Wild AT, Wood LD, Blackford AL, Donehower RC, Hidalgo M, Schulick RD, Edil BH, Choti MA, Hruban RH, Pawlik TM, Cameron JL, Laheru DA, Iacobuzio-Donahue CA, Wolfgang CL.

Int J Radiat Oncol Biol Phys. 2013 Nov 1;87(3):458-9. doi: 10.1016/j.ijrobp.2013.06.2039. No abstract available.

Supplemental Content

Loading ...
Support Center